Eureka Therapeutics Announces Publication of Preclinical Study Demonstrating Selective Depletion of Tregs Using Foxp3 Targeting TCR-mimic Antibody
Eureka Therapeutics Announces Publication of Preclinical Study Demonstrating GPRC5D as a Promising Target for Antibody-Based Therapies in Multiple Myeloma
Eureka Therapeutics Announces Appointment Of Dr. Hanzhong Li As Senior Vice President Of Corporate Development
Eureka Therapeutics announces US FDA Clearance of IND Application for Phase 1/2 Trial of ET140202 ARTEMIS T-Cell Therapy, for the Treatment of Liver Cancer
